Full Data Set News Today

Continued Strong Growth with WAKIX® Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,800...

Full Data Set from Phase I First-in-Human Helped Establish Doses for Phase IIA Multiple Ascending Dose StudyATLANTA--(BUSINESS WIRE)--$ACAD #ACImmune--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodeg...